Arsanis, Inc. Appoints Michael P. Gray As Chief Financial Officer And Chief Business Officer

WALTHAM, Mass. & VIENNA, Austria--(BUSINESS WIRE)--Arsanis, Inc., a clinical-stage biopharmaceutical company focused on monoclonal antibody approaches for the prevention and treatment of serious infectious diseases, today announced that Michael P. Gray has joined the company as chief financial officer and chief business officer.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.